Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer's Disease Neuroimaging Initiative
Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer's Disease Neuroimaging Initiative
复制标题
DOI：
10.1002/dad2.12026
复制
发表时间：
2020-01-01
影响因子：
5.3
通讯作者：
Sevlever, Gustavo
中科院分区：
文献类型：
--
作者：
Allegri, Ricardo F.;Chrem Mendez, Patricio;Sevlever, Gustavo
PurposeTo描述结果的淀粉样蛋白，Tau，神经变性（ATN）的研究框架分类在阿根廷阿尔茨海默氏病神经影像学倡议（arg-ADNI）cohol.Methods23例轻度认知功能障碍（MCI），12痴呆的阿尔茨海默氏症型（DAT），和14名正常对照进行了研究后的ADNI 2协议。根据是否存在β淀粉样蛋白的生物标志物对患者进行分类（A β; A：淀粉样蛋白正电子发射断层扫描[PET]或脑脊液[CSF] A β 42），tau（T：CSF磷酸化tau）和神经变性（N：CSF总-tau，氟脱氧葡萄糖[FDG]-PET扫描，或结构磁共振成像[MRI]扫描）。结果在91%的轻度痴呆患者，20%的早期MCI患者，46%的晚期MCI患者和14%的对照组。在8%的轻度痴呆、20%的早期MCI、15%的晚期MCI和7%的对照受试者中发现疑似非AD病理生理学（SNAP，A-T-N+）。5年随访后痴呆的转化率分别为85%在A+T+N+ MCI患者和50%在A-T-N+ patients.ConclusionsWe目前初步5年的随访结果的区域ADNI的基础上AD生物标志物和ATN分类。
PurposeTo describe results of the Amyloid, Tau, Neurodegeneration (ATN) research framework classification in the Argentine-Alzheimer's Disease Neuroimaging Initiative (arg-ADNI) cohort.MethodsTwenty-three patients with mild cognitive impairment (MCI), 12 dementia of Alzheimer's type (DAT), and 14 normal controls were studied following the ADNI2 protocol. Patients were categorized according to presence or absence of the biomarkers for amyloid beta (A beta; A: amyloid positron emission tomography [PET] scan or cerebrospinal fluid [CSF] A beta 42), tau (T: CSF phosphorylated-tau), and neurodegeneration (N: CSF total-tau, fluorodeoxyglucose [FDG]-PET scan, or structural magnetic resonance imaging [MRI] scan).ResultsA+T+N+ biomarker profile was identified at baseline in 91% of mild dementia patients, 20% of early MCI patients, 46% of late MCI patients, and 14% of control subjects. Suspected non-AD pathophysiology (SNAP, A-T-N+) was found in 8% of mild dementia, 20% of early MCI, 15% of late MCI, and 7% of control subjects. Conversion rates to dementia after 5-year follow-up were 85% in A+T+N+ MCI patients and 50% in A-T-N+ patients.ConclusionsWe present initial 5-year follow-up results of a regional ADNI based on AD biomarkers and the ATN classification.